Mid Cap Improvers

Seeking the best mid cap growth stocks in healthcare for 2026? The Mid Cap Improvers portfolio delivers a concentrated strategy focused on undervalued healthcare stocks poised for significant upside. With just two holdings and 100% sector allocation, this approach serves as a targeted alternative to broad healthcare ETFs, aiming for capital appreciation through companies showing operational improvements and pipeline potential in a recovering market environment. In Q1 2026, investors are closely watching current valuations in biotech as interest rates stabilize and innovation accelerates. The portfolio allocates 66.7% to Alkermes Plc (ALKS), a leader in central nervous system and oncology therapies with strong clinical momentum, and 33.3% to Aclaris Therapeutics Inc (ACRS), which is advancing novel treatments in dermatology and immunology. These selections emphasize stocks with attractive risk-reward profiles amid sector tailwinds. This concentrated portfolio suits aggressive growth investors and those building high-conviction healthcare exposure rather than passive income seekers or beginner investors. Key considerations include elevated volatility from low diversification, regulatory risks in biotech, and healthcare sector headwinds like pricing pressures that could impact returns.